Analysis of prognostic factors of extensive disease-small cell lung cancer
LI Linlu1,2* MAO Yun1,2* CHU Xuelei1,2 SU Yixin1 JIA Bohui1 XUE Peng1 ZHU Shijie1
1.Department of Oncology, Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing 100102, China;
2.Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China
Abstract：Objective To investigate the prognostic factors of extensive disease-small cell lung cancer. Methods The clinical data of 157 patients with extensive disease-small cell lung cancer who were hospitalized in China-Japan Friendship Hospital and Wangjing Hospital of Chinese Academy of Chinese Medical Sciences from January 2011 to January 2019 were analyzed retrospectively. Log-Rank test was used for univariate analysis, Kaplan-Meier method was used for comparison of survival curve between groups, and multivariate COX proportional hazard regression model was used for multivariate analysis of variables with statistically significant difference indicated by univariate analysis. Results Six factors, including patient gender, whether have presence of obstructive pneumonia at the time of diagnosis, liver metastasis, whether have thoracic radiation therapy, number of cycles of first-line chemotherapy, and number of cycles of second-line chemotherapy, were independent influencing factors for prognosis of extensive disease-small cell lung cancer (P ＜ 0.05). Among them, female, the first-line chemotherapy ≥one cycle, number of the second-line chemotherapy cycles four to six cycles, and have thoracic radiation therapy were protective factors for the prognosis of extensive disease-small cell lung cancer patients (P ＜ 0.05), and presence of obstructive pneumonia at the time of diagnosis and liver metastasis were risk factors for the prognosis of extensive disease-small cell lung cancer patients (P ＜ 0.05). Conclusion Extensive disease-small cell lung cancer patients with female gender, the first-line chemotherapy cycles ≥one cycle, and the second-line chemotherapy cycles four to six cycles, have thoracic radiation therapy, have better prognosis, while extensive disease-small cell lung cancer patients with obstructive pneumonia and liver metastasis at the time of diagnosis have worse prognosis.
[1] Bray F，Ferlay J，Soerjomataram I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
[2] Mamdani H，Induru R，Jalal SI. Novel therapies in small cell lung cancer [J]. Transl Lung Cancer Res，2015，4（5）：533-544.
[3] Slotman B，Faivre-Finn C，Kramer G，et al. Prophylactic cranial irradiation in extensive small-cell lung cancer [J]. N Engl J Med，2007，357（7）：664-672.
[4] Prabavathy D, Ramadoss N. Heterogeneity of Small Cell Lung Cancer Stem Cells [J]. Adv Exp Med Biol，2019， 1139：41-57.
[5] Low M，Ben-Or S. Thoracic Surgery in Early-Stage Small Cell Lung Cancer [J]. Thorac Surg Clin，2018，28（1）：9-14.
[6] Wang W，Hodkinson P，Mclaren F，et al. Histologic assessment of tumor-associated CD45（+）cell numbers is an independent predictor of prognosis in small cell lung cancer [J]. Chest，2013，143（1）：146-151.
[7] Slotman BJ，van Tinteren H，Praag JO，et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial [J]. Lancet，2015，385（9962）：36-42.
[8] Singh S，Parulekar W，Murray N，et al. Influence of sex on toxicity and treatment outcome in small-cell lung cancer [J]. J Clin Oncol，2005，23（4）：850-856.
[9] Wheatley-Price P，Ma C，Ashcroft LF，et al. The strength of female sex as a prognostic factor in small-cell lung cancer：a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit [J]. Ann Oncol，2010，21（2）：232-237.
[10] Travis WD. Pathology and diagnosis of neuroendocrine tumors：lung neuroendocrine [J]. Thorac Surg Clin，2014， 24（3）：257-266.
[11] 包晓薇，李丹，宋晨，等.小细胞肺癌发生阻塞性肺炎相关因素分析[J].中国微生态学杂志，2014，26（5）：534-536.
[12] Spratt JS Jr，Spjut HJ，Roper CL. The frequency distribution of the rates of growth and the estimated duration of primary pulmonary carcinomas [J]. Cancer，1963，16：687-693.
[13] 陈筱玲，方健，聂鋆，等.160例老年小细胞肺癌预后多因素分析[J].中国肺癌杂志，2014，17（1）：15-23.
[14] 胡爱民，胡范彬，郑华，等.120例远处转移小细胞肺癌患者的生存因素分析[J].癌症进展，2018，16（10）：1238-1241.
[15] van Meerbeeck JP，Fennell DA，De Ruysscher DK. Small-cell lung cancer [J]. Lancet，2011，378（9804）：1741-1755.
[16] Rodriguez E，Lilenbaum RC. Small cell lung cancer：past，present，and future [J]. Curr Oncol Rep，2010，12（5）：327-334.
[17] Kubota K，Hida T，Ishikura S，et al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy （JCOG0202）：a randomised phase 3 study [J]. Lancet Oncol，2014，15（1）：106-113.
[18] 任晓旭，马锐.广泛期小细胞肺癌的临床特征及预后因素分析[J].现代肿瘤医学，2019（24）：4365-4369.
[19] 王中玉，史清明.154例小细胞肺癌预后因素分析[J].临床肺科杂志，2018，23（9）：1572-1577.
[20] 金倩文，冯国生.局部晚期非小细胞肺癌治疗现状及趋势[J].疑难病杂志，2019，18（8）：860-864.
[21] Yee D，Butts C，Reiman A，et al. Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer [J]. Radiother Oncol，2012，102（2）：234-238.
2020, Vol. 17 
京公网安备 11010502046598号